[Close]

Reprints and correspondence:

Stephen M. Stahl, MD, PhD
Brainstorms
Neuroscience Education Institute
1930 Palomar Point Way, Ste 103
Carlsbad, CA 92008
E-mail: smstahl@psychiatrist.com

Potential conflicts of interest for Stephen M. Stahl, MD, PhD

Updated June 11, 2010

Over the past 12 months (January 2009–January 2010), Dr Stahl has served as a Consultant to Allergan, AstraZeneca, BioMarin, BioVail, Boehringer Ingelheim, Bristol Myers-Squibb, Cenerex, Covance, Cypress Bioscience, Dainippon Sumitomo, Eisai, Eli Lilly, Forest, GlaxoSmithKline, Labopharm, Lundbeck, Marinus, Meda Corp, Meiji, Merck, Novartis, Pfizer, Pfizer Canada, Pierre Fabre, PamLab, Prexa Pharmaceuticals, Propagate Pharma, Royalty Pharma, Sanofi, Schering Plough Corporation, Shire, SK Corporation, Soffinova, Solvay, Vanda, and Wyeth. He has served on speakers bureaus for Pfizer Inc, Wyeth Pharmaceuticals, and Schering Plough Corporation and has received research and/or grant support from AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Cephalon, Dainippon, Eli Lilly, Forest, Lundbeck, Novartis, PamLabs, Pfizer Inc, Pfizer Canada, Pharmasquire, Sanofi Aventis, Schering Plough, Shire, and  Wyeth.

Academic Affiliation:

Adjunct professor of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge, UK.

Subscribe to the Journal

Psychiatrist.com Home          Keyword Search

Close [X]

Search Our Sites

Enter search terms below (keywords, titles, authors, or subjects). Then select a category to search and press the Search button. All words are assumed to be required. To search for an exact phrase, put it in quotes. To exclude a term, precede it with a minus sign (-).

Keyword search:

Choose a category:

Choosing the appropriate category will greatly improve your chances of finding the best match.

All files at our sites: J Clin Psychiatry, Primary Care Companion, CME Institute, and MedFair

Search materials from our journals:

Abstracts from The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements

PDFs of the full text of The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements (paid subscribers)

PDFs of the full text of The Primary Care Companion, 1999–present

Search CME offerings:

CME Institute, including CME from journals , supplements, and Web activities for instant CME credit (registered users); also includes information about our CME program

CME activities from regular issues of The Journal of Clinical Psychiatry (registered users)

CME Supplements from The Journal of Clinical Psychiatry (registered users)

Brainstorms

Brainstorms, written by Stephen M. Stahl, MD, PhD, is a feature of The Journal of Clinical Psychiatry aimed at providing updates of novel concepts emerging from the neurosciences that have relevance to practicing psychiatrists.

2010

The Serotonin-7 Receptor as a Novel Therapeutic Target. November 2010

[Full Text]

Illustrating the Circuits of Sexual Desire. September 2010

[Full Text]

Targeting Circuits of Sexual Desire as a Treatment Strategy for Hypoactive Sexual Desire Disorder. July 2010

[Full Text]

Circuits of Sexual Desire in Hypoactive Sexual Desire Disorder. May 2010

[Full Text]

Mechanism of Action of α2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms. March 2010

[Full Text]

Mechanism of Action of Stimulants in Attention-Deficit/Hyperactivity Disorder. January 2010

[Full Text]

2009

Combining Antidepressant Therapies From the Initiation of Treatment: A Paradigm Shift for Major Depression. November 2009

[Full Text]

Epigenetics and Methylomics in Psychiatry. September 2009

[Full Text]

The Prefrontal Cortex Is Out of Tune in Attention-Deficit/Hyperactivity Disorder. July 2009

[PDF]

Norepinephrine and Dopamine Regulate Signals and Noise in the Prefrontal Cortex. May 2009

[PDF]

Vasomotor Symptoms and Depression in Women, Part 2: Treatments That Cause Remission and Prevent Relapses of Major Depressive Episodes Overlap With Treatments for Vasomotor Symptoms. March 2009

[PDF]

Vasomotor Symptoms and Depression in Women, Part 1: Role of Vasomotor Symptoms in Signaling the Onset or Relapse of a Major Depressive Episode. January 2009

[PDF]

[top]

2008

The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition? November 2008

[PDF]

l-Methylfolate: A Vitamin for Your Monoamines. September 2008

[PDF]

[top]

2005

Is Psychopharmacologic "Inoculation" Effective in Preventing Posttraumatic Stress Disorder? January 2005

[PDF]

[top]

2004

Preemptive Analgesia: Is Pain Less Costly When You Pre-Pay For It? December 2004

[PDF]

Prophylactic Antipsychotics: Do They Keep You From Catching Schizophrenia? November 2004

[PDF]

Drug Combinations for Bipolar Spectrum Disorders: Evidence-Based Prescribing or Prescribing-Based Evidence? October 2004

[PDF]

Psychopharmacology of Anticonvulsants: Levetiracetam as a Synaptic Vesicle Protein Modulator. September 2004

[PDF]

Mechanism of Action of α2δ Ligands: Voltage Sensitive Calcium Channel (VSCC) Modulators. August 2004

[PDF]

Mechanism of Action of Voltage Sensitive Sodium Channel Modulators. July 2004

[PDF]

Anticonvulsants as Mood Stabilizers and Adjuncts to Antipsychotics: Valproate, Lamotrigine, Carbamazepine, Oxcarbazepine and Actions at Voltage-Gated Sodium Channels. June 2004

[PDF]

Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as α2δ Ligands at Voltage-Gated Calcium Channels. May 2004

[PDF]

Anticonvulsants as Anxiolytics, Part 2: Pregabalin and Gabapentin as α2δ Ligands at Voltage-Gated Calcium Channels. April 2004

[PDF]

Anticonvulsants as Anxiolytics, Part 1: Tiagabine and Other Anticonvulsants With Actions on GABA. March 2004

[PDF]

Psychopharmacology of Anticonvulsants: Do All Anticonvulsants Have the Same Mechanism of Action? February 2004

[PDF]

Symptoms and Circuits, Part 3: Schizophrenia. January 2004

[PDF]

[top]

2003

Symptoms and Circuits, Part 2: Anxiety Disorders, December 2003

[PDF]

Symptoms and Circuits, Part 1: Major Depressive Disorder. November 2003

[PDF]

Deconstructing Psychiatric Disorders, Part 2: An Emerging, Neurobiologically Based Therapeutic Strategy for the Modern Psychopharmacologist. October 2003

[PDF]

Deconstructing Psychiatric Disorders, Part 1: Genotypes, Symptom Phenotypes, and Endophenotypes. September 2003

[PDF]

Here Today and Not Gone Tomorrow: The Curse of Chronic Pain and Other Central Sensitization Syndromes. August 2003

[PDF]

Antidepressants and Somatic Symptoms: Therapeutic Actions Are Expanding Beyond Affective Spectrum Disorders to Functional Somatic Syndromes. July 2003

[PDF]

The Ups and Downs of Novel Antiemetic Drugs, Part 2: An Illustration. June 2003

[PDF]

The Ups and Downs of Novel Antiemetic Drugs, Part 1: Substance P, 5-HT, and the Neuropharmacology of Vomiting. May 2003

[PDF]

At Long Last, Long-Lasting Psychiatric Medications: An Overview of Controlled-Release Technologies. April 2003

[PDF]

Neurotransmission of Cognition, Part 3: Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. March 2003

[PDF]

Neurotransmission of Cognition, Part 2: Selective NRIs Are Smart Drugs: Exploiting Regionally Selective Actions on Both Dopamine and Norepinephrine to Enhance Cognition. February 2003

[PDF]

Neurotransmission of Cognition, Part 1: Dopamine Is a Hitchhiker in Frontal Cortex: Norepinephrine Transporters Regulate Dopamine. January 2003

[PDF]

[top]

2002

"The Metabolic Syndrome": Psychopharmacologists Should Weigh the Evidence for Weighing the Patient. December 2002

[PDF]

Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression? November 2002

[PDF]

Independent Actions on Fear Circuits May Lead to Therapeutic Synergy for Anxiety When Combining Serotonergic and GABAergic Agents. October 2002

[PDF]

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder. September 2002

[PDF]

Mirror, Mirror on the Wall, Which Enantiomer Is Fairest of Them All? August 2002

[PDF]

Psychopharmacology of Wakefulness: Pathways and Neurotransmitters. July 2002

[PDF]

Awakening to the Psychopharmacology of Sleep and Arousal: Novel Neurotransmitters and Wake-Promoting Drugs. June 2002

[PDF]

The Psychopharmacology of Painful Physical Symptoms in Depression. May 2002

[PDF]

Does Depression Hurt? April 2002

[PDF]

Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes. March 2002

[PDF]

Antipsychotic Polypharmacy: Squandering Precious Resources? February 2002

[PDF]

The Psychopharmacology of Energy and Fatigue. January 2002

[PDF]

[top]

2001

Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2: Illustrating Their Mechanism of Action. December 2001

[PDF]

Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 1: "Goldilocks" Actions at Dopamine Receptors. November 2001

[PDF]

"Hit-and-Run" Actions at Dopamine Receptors, Part 2: Illustrating Fast Dissociation From Dopamine Receptors That Typifies Atypical Antipsychotics. October 2001

[PDF]

"Hit-and-Run" Actions at Dopamine Receptors, Part 1: Mechanism of Action of Atypical Antipsychotics. September 2001

[PDF]

Gut Feelings About Irritable Bowel Syndrome. August 2001

[PDF]

Fibromyalgia: The Enigma and the Stigma. July 2001

[PDF]

Natural Estrogen as an Antidepressant for Women. June 2001

[PDF]

Effects of Estrogen on the Central Nervous System. May 2001

[PDF]

Why Drugs and Hormones May Interact in Psychiatric Disorders. April 2001

[PDF]

The Psychopharmacology of Sex, Part 2: Effects of Drugs and Disease on the 3 Phases of Human Sexual Response. March 2001

[PDF]

The Psychopharmacology of Sex, Part 1: Neurotransmitters and the 3 Phases of the Human Sexual Response. February 2001

[PDF]

Does Evidence From Clinical Trials in Psychopharmacology Apply in Clinical Practice? January 2001

[PDF]

[top]

2000

New Drug Discovery in the Postgenomic Era: From Genomics to Proteomics. December 2000

[PDF]

The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action. November 2000

[PDF]

The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 1: Their Similarities Are Different. October 2000

[PDF]

Paying Attention to Your Acetylcholine, Part 2: The Function of Nicotinic Receptors. September 2000

[PDF]

Paying Attention to Your Acetylcholine, Part 1: Structural Organization of Nicotinic Receptors. August 2000

[PDF]

The 7 Habits of Highly Effective Psychopharmacologists, Part 4: Developing and Implementing the Vision. July 2000

[PDF]

The 7 Habits of Highly Effective Psychopharmacologists, Part 3: Sharpen the Saw With Selective Choices of Continuing Medical Education Programs. June 2000

[PDF]

The 7 Habits of Highly Effective Psychopharmacologists, Part 2: Begin With the End in Mind. May 2000

[PDF]

The 7 Habits of Highly Effective Psychopharmacologists: Overview. April 2000

[PDF]

Blue Genes and the Mechanism of Action of Antidepressants. March 2000

[PDF]

Blue Genes and the Monoamine Hypothesis of Depression. February 2000

[PDF]

Molecular Neurobiology for Practicing Psychiatrists, Part 5: How a Leucine Zipper Can Turn On Genes: Immediate-Early Genes Activate Late-Gene Expression in the Brain. January 2000

[PDF]

[top]

1999

Molecular Neurobiology for Practicing Psychiatrists, Part 4: Transferring the Message of Chemical Neurotransmission From Presynaptic Neurotransmitter to Postsynaptic Gene Expression. December 1999

[PDF]

Molecular Neurobiology for Practicing Psychiatrists, Part 3: How Second Messengers "Turn On" Genes by Activating Protein Kinases and Transcription Factors. November 1999

[PDF]

Molecular Neurobiology for Practicing Psychiatrists, Part 2: How Neurotransmitters Activate Second Messenger Systems. October 1999

[PDF]

Molecular Neurobiology for Practicing Psychiatrists, Part 1: Overview of Gene Activation by Neurotransmitters. September 1999

[PDF]

Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. August 1999

[PDF]

Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret? July 1999

[PDF]

Antidepressants: The Blue-Chip Psychotropic for the Modern Treatment of Anxiety Disorders. June 1999

[PDF]

Mergers and Acquisitions Among Psychotropics: Antidepressant Takeover of Anxiety May Now Be Complete. May 1999

[PDF]

Why Settle for Silver, When You Can Go for Gold? Response vs. Recovery as the Goal of Antidepressant Therapy. April 1999

[PDF]

Peptides and Psychiatry, Part 3: Substance P and Serendipity: Novel Psychotropics Are a Possibility. March 1999

[PDF]

Substance P and the Neurokinins: Novel Peptide Neurotransmitters in Psychopharmacology. February 1999

[PDF]

Peptides and Psychiatry, Part 1: How Synthesis of Neuropeptides Differs From Classical Neurotransmitter Synthesis. January 1999

[PDF]

[top]

1998

Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor. December 1998

[PDF]

Getting Stoned Without Inhaling: Anandamide Is the Brain's Natural Marijuana. November 1998

[PDF]

How to Appease the Appetite of Psychotropic Drugs. October 1998

[PDF]

Neuropharmacology of Obesity: My Receptors Made Me Eat It. September 1998

[PDF]

What Makes an Antipsychotic Atypical?. August 1998

[PDF]

Not So Selective Serotonin Reuptake Inhibitors. July 1998

[PDF]

When Neurotrophic Factors Get on Your Nerves: Therapy for Neurodegenerative Disorders. June 1998

[PDF]

Recognition Molecules Are Trailblazers for Axon Pathways. May 1998

[PDF]

Brain Tonics for Brain Sprouts: How Neurotrophic Factors Fertilize Neurons. April 1998

[PDF]

Nitric Oxide Physiology and Pharmacology. March 1998

[PDF]

How Psychiatrists Can Build New Therapies for Impotence. February 1998

[PDF]

Brain Fumes: Yes, We Have NO Brain Gas. 1998

[PDF]

[top]

1997

Serotonin: It's Possible to Have Too Much of a Good Thing. December 1997

[PDF]

Sex Therapy in Psychiatric Treatment Has a New Partner: Reproductive Hormones. November 1997

[PDF]

Estrogen Makes the Brain a Sex Organ. October 1997

[PDF]

"Awakening" From Schizophrenia: Intramolecular Polypharmacy and the Atypical Antipsychotics. September 1997

[PDF]

Are Two Antidepressant Mechanisms Better Than One? August 1997

[PDF]

Mental Illness May Be Damaging to Your Brain. July 1997

[PDF]

Excitotoxicity and Neuroprotection. June 1997

[PDF]

Apoptosis: Neuronal Death by Design. May 1997

[PDF]

[top]